Note 4 - Trade Receivables

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Trade Receivables [Text Block]

Note 4 – Trade Receivables

Product Sales

Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO® and RAPIVAB®. At December 31, 2021 and 2020, receivables related to sales of ORLADEYO were $27,384 and $149, respectively. At December 31, 2021 and 2020, receivables related to sales of RAPIVAB were $49 and $254, respectively. No reserve or allowance amounts were recorded as of December 31, 2021 and December 31, 2020, respectively.

Collaborations

At December 31, 2021 and 2020, the Company had the following receivables from collaborations:

	December 31, 2021
	Billed		Unbilled		Total
U.S. Department of Health and Human Services, net	$	5	$	1,670	$	1,675
Royalty receivables from partners		305		−		305
Total receivables from collaborators	$	310	$	1,670	$	1,980

	December 31, 2020
	Billed		Unbilled		Total
U.S. Department of Health and Human Services, net	$	−	$	5,402	$	5,402
Royalty receivables from partners		2,816		25		2,841
Total receivables from collaborators	$	2,816	$	5,427	$	8,243

As of December 31, 2021, the Company maintained a reserve of $701 related to royalties associated with Green Cross. No reserve was recorded at December 31, 2020.